• 2021
  Bazin MA, Cojean S, Pagniez F, Bernadat G, Cavé C, Ourliac-Garnier I, Nourrisson MR, Morgado C, Picot C, Leclercq O, Baratte B, Robert T, Späth GF, Rachidi N, Bach S, Loiseau PM, Le Pape P, Marchand P, , In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition., Eur J Med Chem 2021 Jan; 210(): 112956.
• 2016
  Durieu E, Prina E, Leclercq O, Oumata N, Gaboriaud-Kolar N, Vougogiannopoulou K, Aulner N, Defontaine A, No JH, Ruchaud S, Skaltsounis AL, Galons H, Späth GF, Meijer L, Rachidi N, , From Drug Screening to Target Deconvolution: a Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity., Antimicrob Agents Chemother 2016 05; 60(5): 2822-33.
• 2014
  Cayla M, Rachidi N, Leclercq O, Schmidt-Arras D, Rosenqvist H, Wiese M, Späth GF, , Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability., PLoS Pathog 2014 Sep; 10(9): e1004347.
• 2014
  Dacher M, Morales MA, Pescher P, Leclercq O, Rachidi N, Prina E, Cayla M, Descoteaux A, Späth GF, , Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses., Mol Microbiol 2014 Jul; 93(1): 146-66.
• 2014
  Rachidi N, Taly JF, Durieu E, Leclercq O, Aulner N, Prina E, Pescher P, Notredame C, Meijer L, Späth GF, , Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection., Antimicrob Agents Chemother 2014 ; 58(3): 1501-15.
• 2013
  Leclercq O, Bartho K, Duelsner E, von Kleist L, Gherardini PF, Palmeri A, Helmer-Citterich M, Baumgart S, Späth GF, , Enrichment of Leishmania donovani ATP-binding proteins using a staurosporine capture compound., J Proteomics 2013 Jun; 86(): 97-104.
• 2012
  Horjales S, Schmidt-Arras D, Limardo RR, Leclercq O, Obal G, Prina E, Turjanski AG, Späth GF, Buschiazzo A, , The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms., Structure 2012 Oct; 20(10): 1649-60.
• 2011
  Schmidt-Arras D, Leclercq O, Gherardini PF, Helmer-Citterich M, Faigle W, Loew D, Späth GF, , Adaptation of a 2D in-gel kinase assay to trace phosphotransferase activities in the human pathogen Leishmania donovani., J Proteomics 2011 Aug; 74(9): 1644-51.
• 2010
  Yau WL, Blisnick T, Taly JF, Helmer-Citterich M, Schiene-Fischer C, Leclercq O, Li J, Schmidt-Arras D, Morales MA, Notredame C, Romo D, Bastin P, Späth GF, , Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability., PLoS Negl Trop Dis 2010 Jun; 4(6): e729.
• 2008
  Jovanic T, Roche B, Attal-Bonnefoy G, Leclercq O, Rougeon F, , Ectopic expression of AID in a non-B cell line triggers A:T and G:C point mutations in non-replicating episomal vectors., PLoS One 2008 Jan; 3(1): e1480.